Compartment-specific PPARδ activity controls the outcome of cancer–immune cell competition and immunotherapy efficacy
Study limitation reported by the research below: “The constitutively active VP16/VP64-PPARδ fusion used in genetic models does not equivalently replicate pharmacological PPARδ activation, limiting direct translation of genetic findings to drug use.”